Search research articles
Contact Us
Filters
Showing results (81-90 of 91) with videos related to
Page
of 10
Sort By:
Journal of Child and Adolescent Psychopharmacology
|
June 20, 2015
Safety and Efficacy from an 8 Week Double-Blind Trial and a 26 Week Open-Label Extension of Asenapine in Adolescents with Schizophrenia
Robert L Findling, Ronald P Landbloom, Mary Mackle, et al.
CNS Drugs
|
January 28, 2021
Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview
Christoph U Correll, Edward Kim, Jennifer Kern Sliwa, et al.
Journal of Medical Economics
|
January 20, 2022
Patient profiles, initial hospital encounter characteristics, and hospital re-encounters of patients with a hospital emergency department visit or inpatient admission for major depressive disorder
Qiaoyi Zhang, Marguerite O'Hara, Carter McCormick, et al.
Neuropsychiatric Disease and Treatment
|
July 2, 2020
Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Hoc Analysis of 3 Similarly Designed Randomized Studies
Maju Mathews, Srihari Gopal, Arun Singh, et al.
Neuropsychiatric Disease and Treatment
|
June 14, 2019
Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia
Maju Mathews, Srihari Gopal, Isaac Nuamah, et al.
Journal of the American Academy of Child and Adolescent Psychiatry
|
November 25, 2015
Asenapine for the Acute Treatment of Pediatric Manic or Mixed Episode of Bipolar I Disorder
Robert L Findling, Ronald L Landbloom, Armin Szegedi, et al.
Patient Preference and Adherence
|
October 11, 2021
Relapse and Treatment Adherence in Patients with Schizophrenia Switching from Paliperidone Palmitate Once-Monthly to Three-Monthly Formulation: A Retrospective Health Claims Database Analysis
Gang Li, Alexander Keenan, Mehmet Daskiran, et al.
BMC Psychiatry
|
August 11, 2023
Esketamine versus placebo on time to remission in major depressive disorder with acute suicidality
Dong-Jing Fu, Qiaoyi Zhang, Ling Shi, et al.
Journal of Affective Disorders
|
February 11, 2021
Comments to Drs. Bahji, Vazquez, and Zarate
Wayne C Drevets, Vanina Popova, Ella J Daly, et al.
Current Medical Research and Opinion
|
June 7, 2016
Paliperidone palmitate: Japanese postmarketing mortality results in patients with schizophrenia
Phillip Pierce, Srihari Gopal, Adam Savitz, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 91) with videos related to
Sort By:
Page
of 10
Journal of Child and Adolescent Psychopharmacology
|
June 20, 2015
Safety and Efficacy from an 8 Week Double-Blind Trial and a 26 Week Open-Label Extension of Asenapine in Adolescents with Schizophrenia
Robert L Findling, Ronald P Landbloom, Mary Mackle, et al.
CNS Drugs
|
January 28, 2021
Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview
Christoph U Correll, Edward Kim, Jennifer Kern Sliwa, et al.
Journal of Medical Economics
|
January 20, 2022
Patient profiles, initial hospital encounter characteristics, and hospital re-encounters of patients with a hospital emergency department visit or inpatient admission for major depressive disorder
Qiaoyi Zhang, Marguerite O'Hara, Carter McCormick, et al.
Neuropsychiatric Disease and Treatment
|
July 2, 2020
Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Hoc Analysis of 3 Similarly Designed Randomized Studies
Maju Mathews, Srihari Gopal, Arun Singh, et al.
Neuropsychiatric Disease and Treatment
|
June 14, 2019
Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia
Maju Mathews, Srihari Gopal, Isaac Nuamah, et al.
Journal of the American Academy of Child and Adolescent Psychiatry
|
November 25, 2015
Asenapine for the Acute Treatment of Pediatric Manic or Mixed Episode of Bipolar I Disorder
Robert L Findling, Ronald L Landbloom, Armin Szegedi, et al.
Patient Preference and Adherence
|
October 11, 2021
Relapse and Treatment Adherence in Patients with Schizophrenia Switching from Paliperidone Palmitate Once-Monthly to Three-Monthly Formulation: A Retrospective Health Claims Database Analysis
Gang Li, Alexander Keenan, Mehmet Daskiran, et al.
BMC Psychiatry
|
August 11, 2023
Esketamine versus placebo on time to remission in major depressive disorder with acute suicidality
Dong-Jing Fu, Qiaoyi Zhang, Ling Shi, et al.
Journal of Affective Disorders
|
February 11, 2021
Comments to Drs. Bahji, Vazquez, and Zarate
Wayne C Drevets, Vanina Popova, Ella J Daly, et al.
Current Medical Research and Opinion
|
June 7, 2016
Paliperidone palmitate: Japanese postmarketing mortality results in patients with schizophrenia
Phillip Pierce, Srihari Gopal, Adam Savitz, et al.
Page
of 10